Search

Displaying results 1901 - 1910 of 4590 in total
  1. Drug

    Iopamidol

    go.drugbank.com/drugs/DB08947
    ApprovedInvestigational

    Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.

  2. Drug

    Garetosmab

    go.drugbank.com/drugs/DB16379
    ApprovedInvestigational

    [L63940] By preventing this aberrant signaling, it reduces the formation of new abnormal bone.[L63940] It is administered by intravenous infusion every four weeks. … [L63940] Garetosmab-grts was approved by the FDA on August 19, 2026 to reduce the number of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP.

  3. Drug

    Vandetanib

    go.drugbank.com/drugs/DB05294
    ApprovedInvestigational

    On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.

  4. Drug

    Phenylbutyric acid

    go.drugbank.com/drugs/DB06819
    ApprovedInvestigational

    Phenylbutyric acid is a fatty acid and a derivative of [butyric acid] naturally produced by colonic bacteria fermentation.

  5. Drug

    Hyaluronidase

    go.drugbank.com/drugs/DB14740
    ApprovedInvestigational

    Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hya...

  6. Drug

    Bemnifosbuvir

    go.drugbank.com/drugs/DB19050
    Investigational

    Bemnifosbuvir is under investigation in clinical trial NCT05629962 (SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-risk Outpatients With COVID-19).

  7. Drug

    Tienilic acid

    go.drugbank.com/drugs/DB04831
    ApprovedWithdrawn

    Tienilic acid, or ticrynafen, is a diuretic drug with uric acid-lowering action which was marketed for the treatment of hypertension. It was withdrawn in 1982 after case reports in the United States suggested a link between ticrynafen an...

    Categories: High-Ceiling Diuretics
  8. Drug

    Esketamine

    go.drugbank.com/drugs/DB11823
    ApprovedInvestigational

    [L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression.

  9. Drug

    Valproic acid

    go.drugbank.com/drugs/DB00313
    ApprovedInvestigational

    Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. … In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted

  10. Drug

    Eprenetapopt

    go.drugbank.com/drugs/DB11684
    Investigational

    Eprenetapopt has been used in trials studying the treatment of Prostatic Neoplasms, Hematologic Neoplasms, and Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53.